FDA approves Genentech’s Susvimo for diabetic retinopathy

22 May 2025 - Genentech announced today that the US FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment ...

Read more →

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease

22 May 2025 - Approval based on the positive MATINEE and METREX Phase 3 trials. ...

Read more →

Belite Bio announces FDA granting of breakthrough therapy designation for tinlarebant for the treatment of Stargardt disease

21 May 2025 - Belite Bio today announced that the US FDA has granted breakthrough therapy designation for tinlarebant for ...

Read more →

FDA takes steps to enhance state importation programs to help lower prescription drug prices

21 May 2025 - The US FDA is continuing to take steps to help state importation programs provide safe, effective and ...

Read more →

Zai Lab receives US FDA fast track designation for ZL-1310, a DLL3 targeted antibody drug conjugate, for treatment of extensive stage small cell lung cancer

19 May 2025 - The Company is on track to initiate a pivotal study for ZL-1310 in small cell lung ...

Read more →

PharmaTher announces FDA extends review period for ketamine; new approval goal date 9 August 2025

16 May 2025 -  PharmaTher today announced the US FDA has extended the approval goal date for the review of ...

Read more →

Amneal receives US FDA approval for Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine and cluster headaches in adults

15 May 2025 - Product will be available for appropriate patients in the second half of 2025 ...

Read more →

Kaerus Bioscience's lead candidate KER-0193 granted orphan drug designation and rare paediatric drug designation by US FDA for treatment of Fragile X syndrome

14 May 2025 - Kaerus Bioscience today announces that its lead candidate KER-0193 has been granted both orphan drug designation and ...

Read more →

FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal

15 May 2025 - Today, the FDA approved retifanlimab-dlwr (Zynyz, Incyte) with carboplatin and paclitaxel for the first-line treatment of ...

Read more →

FDA sets PDUFA date for Xspray Pharma’s re-submitted application for Dasynoc

14 May 2025 - The US FDA has acknowledged receipt of Xspray Pharma's re-submitted new drug application) for Dasynoc.  ...

Read more →

FDA extends PDUFA date of Biohaven's troriluzole NDA for rare disease spinocerebellar ataxia

14 May 2025 - Troriluzole would be the first and only FDA approved treatment for spinocerebellar ataxia, if approved. ...

Read more →

BioCryst announces FDA acceptance of NDA for Orladeyo (berotralstat) oral granules in patients with hereditary angioedema aged 2 to 11 years

14 May 2025 - FDA grants priority review of application, with PDUFA target action date of 12 September 2025. ...

Read more →

FDA grants accelerated approval to telisotuzumab vedotin-tllv for non-small cell lung cancer with high c-Met protein overexpression

14 May 2025 - Today, the FDA granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie), a c-Met-directed antibody and microtubule ...

Read more →

FDA approves belzutifan for pheochromocytoma or paraganglioma

14 May 2025 - Today, the FDA approved belzutifan (Welireg, Merck) for adult and paediatric patients 12 years and older ...

Read more →

FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer

8 May 2025 - Today, the FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, ...

Read more →